BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1645 related articles for article (PubMed ID: 26503910)

  • 21. High serum hyaluronic acid and HBV viral load are main prognostic factors of local recurrence after complete radiofrequency ablation of hepatitis B-related small hepatocellular carcinoma.
    Xia F; Lai EC; Lau WY; Ma K; Li X; Bie P; Qian C
    Ann Surg Oncol; 2012 Apr; 19(4):1284-91. PubMed ID: 21913016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma.
    Lee MH; Kim SU; Kim DY; Ahn SH; Choi EH; Lee KH; Lee DY; Seong J; Han KH; Chon CY; Park JY
    J Gastroenterol Hepatol; 2012 Feb; 27(2):313-22. PubMed ID: 21793906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.
    Lee YK; Kim SU; Kim DY; Ahn SH; Lee KH; Lee DY; Han KH; Chon CY; Park JY
    BMC Cancer; 2013 Jan; 13():5. PubMed ID: 23282286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors.
    Shiina S; Tateishi R; Arano T; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Sato T; Masuzaki R; Kondo Y; Goto T; Yoshida H; Omata M; Koike K
    Am J Gastroenterol; 2012 Apr; 107(4):569-77; quiz 578. PubMed ID: 22158026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
    Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N
    Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study.
    Ji J; Wang H; Li Y; Zheng L; Yin Y; Zou Z; Zhou F; Zhou W; Shen F; Gao C
    PLoS One; 2016; 11(4):e0153227. PubMed ID: 27070780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC.
    Toyoda H; Kumada T; Kaneoka Y; Osaki Y; Kimura T; Arimoto A; Oka H; Yamazaki O; Manabe T; Urano F; Chung H; Kudo M; Matsunaga T
    J Hepatol; 2008 Aug; 49(2):223-32. PubMed ID: 18571271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predisposing factors for recurrence of HBV-related small hepatocellular carcinoma after percutaneous radiofrequency ablation.
    Sohn W; Paik YH; Lee MW; Rhim H; Lim HK; Cho JY; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Scand J Gastroenterol; 2014 Mar; 49(3):373-80. PubMed ID: 24354931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic impact of des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma.
    Harimoto N; Yoshida Y; Kurihara T; Takeishi K; Itoh S; Harada N; Tsujita E; Yamashita YI; Uchiyama H; Soejima Y; Ikegami T; Yoshizumi T; Kawanaka H; Ikeda T; Shirabe K; Saeki H; Oki E; Kimura Y; Maehara Y
    Transplant Proc; 2015 Apr; 47(3):703-4. PubMed ID: 25819732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation.
    Facciorusso A; Del Prete V; Antonino M; Crucinio N; Neve V; Di Leo A; Carr BI; Barone M
    Dig Liver Dis; 2014 Nov; 46(11):1014-9. PubMed ID: 25085684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein.
    Hamamura K; Shiratori Y; Shiina S; Imamura M; Obi S; Sato S; Yoshida H; Omata M
    Cancer; 2000 Apr; 88(7):1557-64. PubMed ID: 10738213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging.
    Gomaa AI; Al-Khatib A; Abdel-Razek W; Hashim MS; Waked I
    World J Gastroenterol; 2015 May; 21(18):5654-62. PubMed ID: 25987792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization.
    Zhou DS; Xu L; Luo YL; He FY; Huang JT; Zhang YJ; Chen MS
    World J Gastroenterol; 2015 May; 21(18):5582-90. PubMed ID: 25987783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. α-Fetoprotein is a potential survival predictor in hepatocellular carcinoma patients with hepatitis B selected for liver transplantation.
    Zhang Q; Shang L; Zang Y; Chen X; Zhang L; Wang Y; Wang L; Liu Y; Mao S; Shen Z
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):544-52. PubMed ID: 24614696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Predictive Power of Serum α-Fetoprotein and Des-γ-Carboxy Prothrombin for Survival Varies by Tumor Size in Hepatocellular Carcinoma.
    Tsugawa D; Fukumoto T; Kido M; Takebe A; Tanaka M; Kuramitsu K; Matsumoto I; Ajiki T; Koyama T; Ku Y
    Kobe J Med Sci; 2015 Mar; 61(5):E124-31. PubMed ID: 27363395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Irregular vascular pattern by contrast-enhanced ultrasonography and high serum Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma.
    Takada H; Tsuchiya K; Yasui Y; Nakakuki N; Tamaki N; Suzuki S; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Asahina Y; Enomoto N; Izumi N
    Cancer Med; 2016 Nov; 5(11):3111-3120. PubMed ID: 27748052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers.
    Tateishi R; Shiina S; Yoshida H; Teratani T; Obi S; Yamashiki N; Yoshida H; Akamatsu M; Kawabe T; Omata M
    Hepatology; 2006 Dec; 44(6):1518-27. PubMed ID: 17133456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Significance of Preoperative Hepatocellular Carcinoma With High
    Yamao T; Yamashita YI; Imai K; Umezaki N; Tsukamoto M; Kitano Y; Arima K; Miyata T; Nakagawa S; Okabe H; Hayashi H; Chikamoto A; Ishiko T; Baba H
    Anticancer Res; 2019 Feb; 39(2):883-889. PubMed ID: 30711971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pre-treatment double- or triple-positive tumor markers are predictive of a poor outcome for patients undergoing radiofrequency ablation for hepatocellular carcinoma.
    Nitta H; Nakagawa S; Kaida T; Arima K; Higashi T; Taki K; Okabe H; Hayashi H; Hashimoto D; Chikamoto A; Ishiko T; Beppu T; Baba H
    Surg Today; 2017 Mar; 47(3):375-384. PubMed ID: 27549776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 83.